Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Mar 5:14:1322501.
doi: 10.3389/fonc.2024.1322501. eCollection 2024.

Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia

Lukas Mayer-Suess  1 , Michael Knoflach  1   2 , Andreas Pircher  3 , Stefan Kiechl  1   2 , Christoph Schmidauer  1 , Eva Hametner  1
Affiliations
Case Reports

Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia

Lukas Mayer-Suess et al. Front Oncol. .

Abstract

We present a case with prolonged Lorlatinib-related dyslipidemia causing internal carotid artery stenosis, putting the patient at risk of cerebrovascular events. Through intensified lipid-lowering treatment and dose reduction of Lorlatinib, LDL-C levels decreased markedly. Surprisingly, the left sided internal carotid artery stenosis dissolved accordingly. Due to the high efficacy of the new selective tyrosine kinase inhibitors and resulting long-term treatment, it is essential to carefully follow-up and include drug specific side effect monitoring. This case emphasizes that Loraltinib-related dyslipidemia has to be taken seriously and treatment should be initiated as promptly as possible. We conclude that in cases were lipid dysregulation remains and Lorlatinib treatment has to be continued, cerebrovascular appraisal through ultrasound should be considered and, if stenosis is evident, intensified treatment regimen of dyslipidemia or dose reduction of Lorlatinib should be discussed in an interdisciplinary setting.

Keywords: LDL-C; Lorlatinib; case report; dyslipidemia; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timeline of treatment, Lorlatinib-related dyslipidemia and dissolving carotid plaque under lipid-lowering therapy (A-C).
See this image and copyright information in PMC

References

    1. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. . Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol Dezember. (2018) 19:1654–67. doi: 10.1016/S1470-2045(18)30649-1 - DOI - PubMed
    1. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, et al. . PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. (2015) 28:70–81. doi: 10.1016/j.ccell.2015.05.010 - DOI - PMC - PubMed
    1. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. . Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. (2016) 6:1118–33. doi: 10.1158/2159-8290.CD-16-0596 - DOI - PMC - PubMed
    1. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. . First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. (2020) 383:2018–29. doi: 10.1056/NEJMoa2027187 - DOI - PubMed
    1. Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, et al. . Clinical management of adverse events associated with lorlatinib. Oncologist. (2019) 24:1103–10. doi: 10.1634/theoncologist.2018-0380 - DOI - PMC - PubMed

Publication types

LinkOut - more resources